Personalized Vaccine for High-Risk Liver Cancer (HCC)
This study is testing a personalized vaccine called GNOS-PV02 along with INO-9012, a plasmid (a small piece of DNA) that helps the immune system, in people with high-risk hepatocellular carcinoma (HCC), a type of liver cancer. You might be able to join if you are at least 18 years old, have a confirmed diagnosis of HCC that has been removed by surgery, and have a good liver score (Child-Pugh Class A). The study aims to see if this treatment can help prevent the cancer from coming back (recurrence-free survival) over a period of up to 5 years. The current recruitment status is unclear.
- Study design
- This is a randomized, open-label (meaning you and your doctors will know which treatment you are receiving), multi-site Phase II study planning to enroll 90 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for recurrence-free survival for up to 5 years after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Recurrence-free survivalUp to 5 years
RFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary HCC, as assessed by the investigator, or death due to any cause, whichever occurs first.